Additional file 1: Table S1. of Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis

Drug resistant TB and MDR-TB prevalence among new and previously treated cases of the study. Table S2. Treatment success rate of acquired drug resistant TB stratified by drug resistance patterns. (DOCX 41 kb

Socio-behavioral and clinical characteristics along with HIV sero-positivity among participating tuberculosis (TB) patients in three provinces of China, 2010 (N = 1032).

<p>Socio-behavioral and clinical characteristics along with HIV sero-positivity among participating tuberculosis (TB) patients in three provinces of China, 2010 (N = 1032).</p

Factors correlated with HIV infection among TB patients in three provinces of China, 2010 (N = 1032).

<p><b>*</b>Model 1 adjusted for site, genders and areas of residence.</p><p>#: Model 2 adjusted for sites, genders, areas of residence, age and annual income.</p><p><a href="mailto:@" target="_blank">@</a>: The model did not work well.</p><p>Boldfaced figures indicated statistically significant results at α = 0.05.</p

Incidence, onset time and seriousness of adverse drug reactions due to directly observed treatment strategy therapy in 4304 Chinese tuberculosis patients.

<p>IQR, inter-quartile range.</p>#<p>The incidence of ADR was standardized for age and gender with direct standardization using one reference population that from national TB epidemic surveillance database of 2008.</p>†<p>It was from initiation of treatment.</p>§<p>Serious ADRs were defined as any untoward medical occurrence that at any dose results in death, requires hospital admission or prolongation of existing hospital stay, results in persistent or significant disability/incapacity, or is life threatening.</p>$<p>It was the time that ADRs were found, not the exact time it happened.</p>‡<p>Nervous system disorders included auditory nerve damage, optic nerve damage, peripheral nervous damage and central nervous system damage.</p>€<p>Others included one with interstitial pneumonia and another with hypokalemia.</p>*<p>For 82 patients got two ADRs, sixteen got three and one got four, 766 cases were detected and the denominator was 4304+82+32+3 = 4421.</p

Baseline Characteristics of 4304 Chinese tuberculosis patients.

<p>IQR, inter-quartile range.</p

Possible risk factors for the smear results at the end of intensive phase and anti- tuberculosis outcomes at the end of consolidation phase, respectively.

<p>IQR, inter-quartile range.</p>*<p>For the data of 51 patients missed, 4253 patients’ data were analyzed.</p>#<p>For the data of 16 patients missed, 4288 patients’ data were analyzed. Successful outcomes defined as the completion of treatment and patients being cured. Unsuccessful outcomes defined as treatment failure, default and death because of ADRs due to DOTS therapy.</p

Impact of ADRs due to directly observed treatment strategy therapy on smear results at the end of intensive phase and anti-TB treatment outcomes.

<p>ADRs, adverse drug reactions; TB, tuberculosis; OR, odds ratio; CI, confidence internal; AR%, attributable risk proportion; PAR%, population attributable risk proportion.</p><p>& A total of 518 patients developed ADRs within the intensive phase. For the data of 51 patients missed, 4253 patients’ data were analyzed.</p>$<p>A total of 649 patients developed ADRs at the end of anti-TB treatment. For the data of 16 patients missing, 4288 patients’ data was analyzed. Successful outcomes defined as the completion of treatment and patients being cured. Unsuccessful outcomes defined as treatment failure, default and death because of ADRs due to DOTS therapy.</p>*<p>Age, gender, TB treatment history and disease history were adjusted using logistic regression analysis.</p>§<p>Age, gender, TB treatment history and HBsAg status were adjusted using logistic regression analysis.</p>#<p>AR% and PAR% were calculated based on adjusted OR, respectively.</p

Causality assessment of adverse drug reactions due to directly observed treatment strategy therapy^*.

*<p>The causality assessment was done following the standards of WHO Uppsala Monitoring Center System by the experts from Center for Drug Reassessment of Chinese State Food and Drug Administration.</p>#<p>Data was presented as number of patients (%).</p

The frequency of symptoms in 106 ATLI cases.^a

a<p>Abbreviation used in table: ATLI, Anti-tuberculosis Drug Induced Liver Injury.</p

Relative risk and attributable risk proportion for anti-TB treatment between ATLI and non-ATLI anti-TB treatment cases.^a

a<p>Abbreviation used in table: TB, tuberculosis; ATLI, Anti-tuberculosis Drug Induced Liver Injury; RR, relative risk; AR%: attributable risk proportion.</p>b<p>Intensive treatment phase: the number of patients was 4292, because 12 patients missed data.</p>c<p>Smear result at 2 months: the number of patients was 4259, because 45 patients missed smear examination.</p>d<p>AR%: it is the percent of the incidence of an outcome in the exposed that is due to the exposure.</p>e<p>Unsuccessful outcomes: A sum of treatment failure, died, default and transfer out.</p>f<p>Successful outcomes: A sum of cure and treatment completed.</p